Cogent Biosciences (COGT) Cash from Investing Activities (2017 - 2026)

Cogent Biosciences (COGT) has reported Cash from Investing Activities for 9 consecutive years, with -$36.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 152.55% year-over-year to -$36.5 million; the TTM figure through Mar 2026 stood at -$505.4 million (down 574.02% YoY), while the FY2025 annual figure was -$399.5 million, down 1143.8% from the prior year.
• Cash from Investing Activities improved to -$36.5 million in Q1 2026 per COGT's latest filing, from -$322.8 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $69.4 million in Q1 2025 and bottomed at -$322.8 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$36.5 million across 5 years, with a median of -$441000.0 in 2022.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 12930.44% — and 2023, when it jumped 13679.14%.
• Cogent Biosciences' Cash from Investing Activities stood at $28.4 million in 2022, then sank by 63.08% to $10.5 million in 2023, then surged by 487.96% to $61.7 million in 2024, then sank by 623.37% to -$322.8 million in 2025, then jumped by 88.7% to -$36.5 million in 2026.
• Business Quant data shows COGT's Cash from Investing Activities at -$36.5 million in Q1 2026, -$322.8 million in Q4 2025, and -$155.0 million in Q3 2025.